These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 12395015)

  • 1. Methylphenidate produces a false-positive urine amphetamine screen.
    Manzi S; Law T; Shannon MW
    Pediatr Emerg Care; 2002 Oct; 18(5):401. PubMed ID: 12395015
    [No Abstract]   [Full Text] [Related]  

  • 2. [The medical treatment of attention deficit hyperactivity disorder (ADHD) with amphetamines in children and adolescents].
    Frölich J; Banaschewski T; Spanagel R; Döpfner M; Lehmkuhl G
    Z Kinder Jugendpsychiatr Psychother; 2012 Sep; 40(5):287-99; quiz 299-300. PubMed ID: 22869222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Test result could mean different things.
    Gourlay D
    Can Fam Physician; 2003 Jan; 49():23-4; author reply 24. PubMed ID: 12602837
    [No Abstract]   [Full Text] [Related]  

  • 4. From attention-deficit/hyperactivity disorder to medical stimulant use to the diversion of prescribed stimulants to non-medical stimulant use: connecting the dots.
    Poulin C
    Addiction; 2007 May; 102(5):740-51. PubMed ID: 17506151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amphetamine and fenproporex levels following multidose administration of fenproporex.
    Cody JT; Valtier S; Stillman S
    J Anal Toxicol; 1999; 23(3):187-94. PubMed ID: 10369328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patients in medical treatment for attention deficit/hyperactivity disorder (ADHD): Are they at risk in drug screening?
    Jensen CM; Breindahl T
    Atten Defic Hyperact Disord; 2019 Sep; 11(3):333-340. PubMed ID: 30536198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced interference by phenothiazines in amphetamine drug of abuse immunoassays.
    Melanson SE; Lee-Lewandrowski E; Griggs DA; Long WH; Flood JG
    Arch Pathol Lab Med; 2006 Dec; 130(12):1834-8. PubMed ID: 17149959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current pharmacotherapy of attention deficit hyperactivity disorder.
    Reddy DS
    Drugs Today (Barc); 2013 Oct; 49(10):647-65. PubMed ID: 24191257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroendocrine responses to methylphenidate and d-amphetamine: applications to attention-deficit disorder.
    Lurie S; O'Quinn A
    J Neuropsychiatry Clin Neurosci; 1991; 3(1):41-50. PubMed ID: 7580171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Confirming proper use of medication: more than one way.
    Berger PB
    Can Fam Physician; 2002 Aug; 48():1292. PubMed ID: 12228954
    [No Abstract]   [Full Text] [Related]  

  • 11. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder.
    Cox DJ; Merkel RL; Moore M; Thorndike F; Muller C; Kovatchev B
    Pediatrics; 2006 Sep; 118(3):e704-10. PubMed ID: 16950962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Priapism associated with the use of stimulant medications and atomoxetine for attention-deficit/hyperactivity disorder in children.
    Eiland LS; Bell EA; Erramouspe J
    Ann Pharmacother; 2014 Oct; 48(10):1350-5. PubMed ID: 24982313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of ephedrine, pseudoephedrine and phenylpropanolamine concentrations in human urine samples and a comparison of the specificity of DRI amphetamines and Abuscreen online (KIMS) amphetamines screening immunoassays.
    Stout PR; Klette KL; Horn CK
    J Forensic Sci; 2004 Jan; 49(1):160-4. PubMed ID: 14979364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aripiprazole causing false positive urine amphetamine drug screen in an adult patient with bipolar disorder.
    Caricasole V; Spagnolo G; Di Bernardo I; Cirnigliaro G; Piccoli E; Dell'Osso B
    Compr Psychiatry; 2019 Oct; 94():152126. PubMed ID: 31518847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequency of false positive amphetamine screens due to bupropion using the Syva EMIT II immunoassay.
    Casey ER; Scott MG; Tang S; Mullins ME
    J Med Toxicol; 2011 Jun; 7(2):105-8. PubMed ID: 21191682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surface-activated chemical ionization ion trap mass spectrometry in the analysis of amphetamines in diluted urine samples.
    Cristoni S; Bernardi LR; Gerthoux P; Gonella E; Mocarelli P
    Rapid Commun Mass Spectrom; 2004; 18(16):1847-55. PubMed ID: 15329879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risks of Stimulant Use for Attention Deficit Hyperactivity Disorder on the Developing Brain: Primum non nocere.
    Stern HP; Lipman J; Andersen SL; Bossaer JB; Thigpen J
    Clin Pediatr (Phila); 2017 Aug; 56(9):805-810. PubMed ID: 28459152
    [No Abstract]   [Full Text] [Related]  

  • 18. Determination of amphetamine and methylphenidate in exhaled breath of patients undergoing attention-deficit/hyperactivity disorder treatment.
    Beck O; Stephanson N; Sandqvist S; Franck J
    Ther Drug Monit; 2014 Aug; 36(4):528-34. PubMed ID: 24452069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Managing stimulant medication for attention-deficit/hyperactivity disorder: an update.
    Wender EH
    Pediatr Rev; 2002 Jul; 23(7):234-6. PubMed ID: 12093933
    [No Abstract]   [Full Text] [Related]  

  • 20. Cross-reactivities of various phenethylamine-type designer drugs to immunoassays for amphetamines, with special attention to the evaluation of the one-step urine drug test Instant-View™, and the Emit® assays for use in drug enforcement.
    Nakanishi K; Miki A; Zaitsu K; Kamata H; Shima N; Kamata T; Katagi M; Tatsuno M; Tsuchihashi H; Suzuki K
    Forensic Sci Int; 2012 Apr; 217(1-3):174-81. PubMed ID: 22154438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.